Evidence-Based Nutraceuticals Derived from Antrodia cinnamomea
Name
foods-14-01212-v3.pdf
Size
2.77 MB
Format
Adobe PDF
Checksum (MD5)
31583ddbcc3dd77a6b2883dd1c302d73
Author(s)
Xu, Chunyuhang
Xie, Qingtong
Kuo, Chien-Liang
Yang, Xin
Huang, Dejian
Date Issued
March 30, 2025
Journal
Foods
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Xu, C.; Xie, Q.; Kuo, C.-L.; Yang, X.; Huang, D. Evidence-Based Nutraceuticals Derived from Antrodia cinnamomea. Foods 2025, 14, 1212.
Version
Final published version
Abstract
Antrodia cinnamomea (A. cinnamomea), a medicinal and edible mushroom endemic to Taiwan, has been traditionally valued as a health tonic. Recent studies have highlighted the diverse specialized metabolites and bioactive potential of this substance, primarily attributed to key secondary metabolites such as benzenoids, maleic and succinic acids, ubiquinone, triterpenoids, and the primary metabolite polysaccharides. These compounds exhibit a broad spectrum of pharmacological properties, including those related to antibacterial, antitumor, anti-inflammation, hepatoprotection, hypoglycaemia, and antioxidant activities, and immunomodulation and gut microbiota regulation. These findings highlight the therapeutic potential of A. cinnamomea and its potential applications in health supplements and functional foods. This review evaluated recent advancements in the cultivation, extraction, and characterization of bioactive compounds from A. cinnamomea, with a particular focus on submerged and solid-state fermentation methods. We hope to provide a comprehensive framework for promoting the efficient and scientific evidence based utilization of A. cinnamomea in novel therapeutic strategies and health-related innovations.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/foods14071212
